Comparison of clinical features among de novo CD5+CD10− DLBCL with and without intravascular/sinusoidal patterning and CD5+CD10− IVLBCL
| Diagnosis . | De novo CD5+CD10− DLBCL . | CD5+CD10− IVLBCL . | P* . | P† . | P‡ . | |
|---|---|---|---|---|---|---|
| No IVL pattern . | IVL pattern . | IVL pattern, primarily . | ||||
| Grouping | DLBCL-NOS | DLBCL-IVL | IVLBCL | — | — | — |
| No. of patients | 60 | 37 | 31 | — | — | — |
| Age at diagnosis, y | ||||||
| Median | 66 | 63 | 68 | .588 | .880 | .579 |
| Range | 22-91 | 36-85 | 44-84 | — | — | — |
| Older than 60 | 41 (68) | 25 (68) | 21 (68) | .937 | .954 | .988 |
| Sex, male/female | 26/34 | 17/20 | 18/13 | .801 | .183 | .319 |
| Performance status, greater than 1 | 17 (28) | 14 (38) | 26 (84) | .330 | < .001 | < .001 |
| Serum LDH level, high§ | 37 (62) | 28 (76) | 29 (94) | .154 | .001 | .046 |
| Stage III/IV | 32 (53) | 25 (68) | 29 (94) | .167 | < .001 | .008 |
| Extranodal involvement‖ | 34 (57) | 25 (68) | 31 (100) | .285 | < .001 | < .001 |
| Extranodal involvement, more than 1 site | 9 (15) | 11 (30) | 20 (65) | .082 | < .001 | .004 |
| IPI | ||||||
| Low | 22 (37) | 7 (19) | 0 (0) | — | — | — |
| Low-intermediate | 14 (23) | 10 (27) | 3 (10) | — | — | — |
| High-intermediate | 7 (12) | 6 (16) | 3 (10) | .177§ | < .001¶ | .001¶ |
| High | 17 (28) | 14 (38) | 25 (81) | .330 | < .001 | < .001 |
| B symptoms present | 17 (28) | 17 (46) | 26 (84) | .077 | < .001 | .001 |
| Tumor cell in BM/PB | 10 (17) | 10 (27) | 27 (87) | .221 | < .001 | < .001 |
| Hepatomegaly | 6 (10) | 10 (27) | 17 (55) | .028 | < .001 | .020 |
| Splenomegaly | 7 (12) | 14 (38) | 24 (77) | .002 | < .001 | .001 |
| Lymphadenopathy | 45 (75) | 26 (70) | 4 (13) | .609 | < .001 | < .001 |
| Diagnosis . | De novo CD5+CD10− DLBCL . | CD5+CD10− IVLBCL . | P* . | P† . | P‡ . | |
|---|---|---|---|---|---|---|
| No IVL pattern . | IVL pattern . | IVL pattern, primarily . | ||||
| Grouping | DLBCL-NOS | DLBCL-IVL | IVLBCL | — | — | — |
| No. of patients | 60 | 37 | 31 | — | — | — |
| Age at diagnosis, y | ||||||
| Median | 66 | 63 | 68 | .588 | .880 | .579 |
| Range | 22-91 | 36-85 | 44-84 | — | — | — |
| Older than 60 | 41 (68) | 25 (68) | 21 (68) | .937 | .954 | .988 |
| Sex, male/female | 26/34 | 17/20 | 18/13 | .801 | .183 | .319 |
| Performance status, greater than 1 | 17 (28) | 14 (38) | 26 (84) | .330 | < .001 | < .001 |
| Serum LDH level, high§ | 37 (62) | 28 (76) | 29 (94) | .154 | .001 | .046 |
| Stage III/IV | 32 (53) | 25 (68) | 29 (94) | .167 | < .001 | .008 |
| Extranodal involvement‖ | 34 (57) | 25 (68) | 31 (100) | .285 | < .001 | < .001 |
| Extranodal involvement, more than 1 site | 9 (15) | 11 (30) | 20 (65) | .082 | < .001 | .004 |
| IPI | ||||||
| Low | 22 (37) | 7 (19) | 0 (0) | — | — | — |
| Low-intermediate | 14 (23) | 10 (27) | 3 (10) | — | — | — |
| High-intermediate | 7 (12) | 6 (16) | 3 (10) | .177§ | < .001¶ | .001¶ |
| High | 17 (28) | 14 (38) | 25 (81) | .330 | < .001 | < .001 |
| B symptoms present | 17 (28) | 17 (46) | 26 (84) | .077 | < .001 | .001 |
| Tumor cell in BM/PB | 10 (17) | 10 (27) | 27 (87) | .221 | < .001 | < .001 |
| Hepatomegaly | 6 (10) | 10 (27) | 17 (55) | .028 | < .001 | .020 |
| Splenomegaly | 7 (12) | 14 (38) | 24 (77) | .002 | < .001 | .001 |
| Lymphadenopathy | 45 (75) | 26 (70) | 4 (13) | .609 | < .001 | < .001 |
Values in parentheses expressed as percentage. P values less than .05 are italicized.
DLBCL-NOS indicates de novo CD5+CD10− DLBCL, not otherwise specified, without intravascular/sinusoidal pattern; DLBCL-IVL, de novo CD5+CD10− DLBCL with intravascular/sinusoidal pattern; IVL pattern, intravascular/sinusoidal pattern; and —, not applicable.
DLBCL-NOS versus DLBCL-IVL.
DLBCL-NOS versus CD5+CD10− IVLBCL.
DLBCL-IVL versus CD5+CD10− IVLBCL.
Higher than the upper limit of the standard range defined by each institution.
Waldeyer ring or spleen was not counted as an extranodal site.
High or high-intermediate versus low or low-intermediate.